Evogene (EVGN) AI Stock Analysis

• Market Cap: $8.20M
• Dividend Yield: N/A
• Average Volume (3M): 115.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: -29.78%
• EPS Growth: 88.96%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.44
• Shares Outstanding: 8,718,193
• 10 Day Avg. Volume: 235,429
• 30 Day Avg. Volume: 115,158
• PEG Ratio: 0.01
• Price to Book (P/B): -7.34
• Price to Sales (P/S): 1.25
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 0.87
• Enterprise Value/Gross Profit: 5.40
• Enterprise Value/Ebitda: -0.80
• 1Y Price Target: $2.50
• Price Target Upside: 127.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.98 ▼(-11.36% Downside)
• Action: Reiterated Date: 11/23/25
• Date: Action: Reiterated 11/23/25

Evogene's overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While the earnings call provided some positive insights into cost management and strategic initiatives, the company's financial instability and bearish technical indicators weigh heavily on the score.

Positive Factors

Strategic Collaborations

Collaborations with industry leaders like Bayer and Corteva enhance Evogene's market position and innovation potential in herbicide development.

AI Technology Advancement

The partnership with Google Cloud to enhance AI capabilities strengthens Evogene's competitive edge in molecular discovery, benefiting pharma and agriculture sectors.

Cost Management

Significant cost reductions improve financial stability and allow for reinvestment in strategic growth areas, supporting long-term sustainability.

Negative Factors

Revenue Decline

Declining revenues highlight challenges in maintaining sales momentum, potentially impacting future growth and financial health.

High Leverage

High leverage increases financial risk and limits flexibility, posing challenges to Evogene's ability to navigate economic fluctuations.

Negative Cash Flows

Persistent negative cash flows indicate operational inefficiencies and may constrain the company's ability to fund growth initiatives.

Evogene Business Overview & Revenue Model

Company Description

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

How the Company Makes Money

Evogene generates revenue through several key streams, including licensing agreements for its proprietary trait technologies to seed companies, which pay for the rights to incorporate Evogene's innovations into their seed products. Additionally, the company earns revenue from collaborations and partnerships with agricultural firms, where it provides research and development services in exchange for fees or revenue-sharing agreements. These partnerships often involve co-development agreements that enable Evogene to leverage its computational biology capabilities to enhance product offerings of its partners. Furthermore, Evogene may also generate income from the sale of bio-based products developed for agricultural use, contributing to its overall revenue model.

Evogene Financial Statement Overview

Summary

Evogene's financial performance is weak, with declining revenues, persistent losses, high leverage, and negative cash flows. Despite minor improvements, the overall financial health is precarious.

Income Statement

Evogene's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a substantial revenue decrease of 22.03%, and the company has consistently reported negative EBIT and EBITDA margins, indicating ongoing operational inefficiencies. Despite a relatively stable gross profit margin, the overall financial health is concerning due to persistent losses.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio in the TTM period, indicating increased leverage and financial risk. The return on equity is positive, but this is due to negative equity, which is not a sustainable position. The equity ratio has decreased over time, reflecting a weakening financial structure. Overall, the balance sheet suggests financial instability and potential liquidity issues.

Cash Flow

Evogene's cash flow statement highlights negative operating and free cash flows, with a slight improvement in free cash flow growth in the TTM period. However, the operating cash flow to net income ratio remains negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but overall cash flow health is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.25M	8.51M	5.64M	1.68M	930.00K	1.04M
Gross Profit	846.00K	3.39M	1.40M	-1.77M	-2.07M	-2.26M
EBITDA	-5.72M	-15.38M	-23.20M	-26.93M	-27.80M	-23.18M
Net Income	-2.75M	-16.48M	-23.88M	-26.64M	-27.79M	-23.37M
Balance Sheet
Total Assets	26.09M	39.86M	51.10M	56.13M	76.30M	71.92M
Cash, Cash Equivalents and Short-Term Investments	15.96M	15.31M	31.06M	35.35M	53.87M	48.23M
Total Debt	2.52M	12.87M	11.51M	11.93M	2.67M	2.44M
Total Liabilities	6.00M	25.03M	22.42M	21.34M	12.88M	15.03M
Stockholders Equity	1.14M	-1.45M	12.05M	27.93M	53.65M	46.05M
Cash Flow
Free Cash Flow	-16.94M	-20.33M	-22.36M	-24.85M	-25.56M	-20.20M
Operating Cash Flow	-16.48M	-19.70M	-21.58M	-23.68M	-24.84M	-19.51M
Investing Cash Flow	16.59M	9.62M	-4.54M	13.27M	-20.44M	9.41M
Financing Cash Flow	-6.21M	4.66M	18.15M	9.34M	30.28M	20.37M

Evogene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.04, and below the 200-day MA of 1.20, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 28.35 is Positive, neither overbought nor oversold. The STOCH value of 8.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVGN.

Evogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$80.49M	-2.44	-70.22%	―	185.71%	79.03%
BOLT	48 Neutral	$8.96M	-0.23	-81.97%	―	-46.88%	34.83%
PHGE	45 Neutral	$8.37M	-0.17	-154.50%	―	―	54.25%
EVGN	43 Neutral	$8.20M	-1.81	―	―	-29.78%	88.96%
KZIA	41 Neutral	$65.64M	-0.51	―	―	-98.25%	63.05%
WINT	39 Underperform	$396.08K	>-0.01	―	―	―	99.09%

Evogene Corporate Events

Evogene Announces CFO Resignation and Finance Leadership Transition

On January 15, 2026, Israel-based Evogene Ltd. reported a senior management change, announcing that Chief Financial Officer Yaron Eldad has submitted his resignation for personal reasons, effective March 31, 2026, with the company clarifying that his departure does not stem from any disagreement over its operations, policies or practices. VP Finance Polina Ravzin, who has held that position since 2022 and previously served in finance roles at DSIT Solutions Ltd. and Acorn Energy Inc., will retain her current role while also assuming the responsibilities of CFO, signaling continuity in Evogene’s financial leadership structure during the transition.

The most recent analyst rating on (EVGN) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.

Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth

On December 30, 2025, Israel-based Evogene Ltd. announced that it has appointed Dr. Olga Nissan as its Vice President of Business Development, effective January 1, 2026, marking a key addition to its leadership team. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceuticals, diagnostics and agri-biotechnology, with previous roles including CEO and Co-Founder of Protica Bio and positions at EcoPhage, BiomX and Teva Pharmaceutical Industries; the company’s leadership expects her expertise in AI-enabled drug discovery, strategic partnerships and company-building to support the scaling of Evogene’s ChemPass AI-driven small-molecule discovery and optimization activities and to strengthen collaborations with industry partners.

The most recent analyst rating on (EVGN) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.

Evogene Reports Q3 2025 Financial Results Amid Strategic Shift

On November 20, 2025, Evogene Ltd. announced its financial results for the third quarter ending September 30, 2025, highlighting a strategic transition towards computational chemistry with a focus on small molecule design. The company reported a significant reduction in operating expenses due to organizational realignment and cost-reduction measures, resulting in a decrease in operating loss compared to the previous year. The sale of Lavie Bio’s assets and MicroBoost AI contributed to a strengthened cash position. Despite a decrease in overall revenue, Evogene is poised for growth with its AI-driven approach, aiming to redefine innovation in pharma and agriculture.

The most recent analyst rating on (EVGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.